-
Colorectal Cancer
-
Breast Cancer
-
Cancer screening
-
Personalized treatment guidance
-
Hereditary cancer testing
-
Monitoring treatment and cancer
-
Advanced cancer therapy selection
Is cancer present?
The Cologuard® test can give you insights
| WHAT | A convenient, noninvasive means of screening adults 45 and older at average risk for colorectal cancer that can be done at home |
| WHY | To effectively detect colorectal cancer through high sensitivity, even in early stages when it is more treatable1-3* |
| HOW | Uses proprietary stool DNA (sDNA) technology to analyze and detect 11 distinct biomarkers that are used to identify colorectal cancer and precancerous polyps1,2 |
Learn More About
*Based on 5-year relative survival.
Indications and Important Risk Information
Cologuard is intended to screen adults 45 years of age and older who are at average risk for colorectal cancer by detecting certain DNA markers and blood in the stool. Do not use if you have had adenomas, have inflammatory bowel disease and certain hereditary syndromes, or a personal or family history of colorectal cancer. Cologuard is not a replacement for colonoscopy in high risk patients. Cologuard performance in adults ages 45-49 is estimated based on a large clinical study of patients 50 and older.
The Cologuard test result should be interpreted with caution. A positive test result does not confirm the presence of cancer. Patients with a positive test result should be referred for colonoscopy. A negative test result does not confirm the absence of cancer. Patients with a negative test result should discuss with their doctor when they need to be tested again. False positives and false negative results can occur. In a clinical study, 13% of people without cancer received a positive result (false positive) and 8% of people with cancer received a negative result (false negative). Rx only.
What treatment options should I pursue?
The Oncotype DX® test can give you insights
| WHAT | A 12-gene genomic test, including 7 cancer-related genes and 5 reference genes4 |
| WHY | To quantify an individual’s risk of recurrence with colorectal cancer and to help determine how an individual’s condition is best managed after surgery4-6 |
| HOW | Through molecular testing of a tumor biopsy sample, individuals and their doctors can leverage the tumor’s underlying biology to guide treatment decisions that fit their unique situation |
Learn More About
Is the cancer hereditary?
The Riskguard™ test can give you insights
| WHAT | A risk assessment tool that can uncover hereditary cancer risk, supporting personalized care |
| WHY | The Riskguard test can assist with informing an individualized plan including targeted therapy, surgical treatment planning, and increased surveillance for second primary cancers. For those without cancer, it can provide risk stratification, which can help inform potential risk-reducing and screening strategies7 |
| HOW | By utilizing a multi-cancer, multigene panel designed to identify germline variants in blood, saliva, and buccal swab samples |
Is the cancer gone or has it returned?
Innovation in development
| WHAT | Exact Sciences is developing the Oncodetect™ test, a tumor-informed molecular residual disease (MRD) test for patients diagnosed with solid tumor cancers |
| WHY | The Oncodetect test is designed to be used in many ways:
|
| HOW | By identifying somatic alterations in DNA extracted from the tumor tissue and detecting a subset of these mutations in circulating tumor DNA (ctDNA) that may be present in an individual’s blood |
Are there personalized options for advanced cancer?
The OncoExTra® test can give you insights
| WHAT | An ultra-comprehensive, ultra-personalized genomic profiling test that looks at DNA+RNA in nearly 20,000 genes8 |
| WHY | To identify the biomarkers associated with targeted therapy, immunotherapy, and clinical trials |
| HOW | Uncovers clinically actionable mutations and fusions through whole-exome, whole-transcriptome, patient-matched tumor-normal sequencing8 |
Learn More About
Innovation in development
| WHAT | Exact Sciences is developing the Oncoliquid™ test, a liquid biopsy test offering a complementary option to tissue-based testing with the OncoExTra test |
| WHY | To identify the most appropriate therapy or clinical trial options for patients with solid tumors, utilizing a simple blood draw |
| HOW | Identifies clinically actionable mutations through detecting and interrogating fragments of circulating tumor DNA (ctDNA) found in the patient’s bloodstream |
-
Personalized treatment guidance
-
Radiation benefit guidance
-
Hereditary cancer testing
-
Monitoring treatment and cancer
-
Advanced cancer therapy selection
What treatments options should I pursue?
The Oncotype DX® test can give you insights
| WHAT | A 21-gene genomic test, including 16 cancer-related genes and 5 reference genes9 |
| WHY | To help determine whether an individual diagnosed with early-stage breast cancer may benefit from chemotherapy and to quantify their individual risk of recurrence9-12 |
| HOW | Analysis of a tumor’s unique biology through molecular testing helps individuals and their doctors make personalized chemotherapy treatment decisions in early-stage HR+, HER2- breast cancer |
Learn More About
Should I consider radiation?
The Oncotype DX® test can give you insights
| WHAT | A 12-gene genomic test that provides an individualized assessment to help determine the risk of local recurrence for those diagnosed with ductal carcinoma in situ (DCIS)13-15 |
| WHY | To help inform an individual’s radiation therapy decision by providing information that goes beyond traditional clinical and pathological factors13-15 |
| HOW | Analysis of a tumor’s unique biology through molecular testing helps individuals and their doctors make personalized radiotherapy treatment decisions |
Learn More About
Innovation in development
The Oncotype DX Breast Radiation Score™ test is an
innovation in development that is designed to help determine
individual benefit from radiation therapy after breast-conserving
surgery. This test is based on the first genomic
signature known to forecast both the likelihood of local-regional
recurrence as well as benefit from radiotherapy
Is the cancer hereditary?
The Riskguard™ test can give you insights
| WHAT | A risk assessment tool that can uncover hereditary cancer risk, supporting personalized care |
| WHY | The Riskguard test can assist with informing an individualized plan including targeted therapy, surgical treatment planning, and increased surveillance for second primary cancers. For those without cancer, it can provide risk stratification, which can help inform potential risk-reducing and screening strategies16,17 |
| HOW | By utilizing a multi-cancer, multigene panel designed to identify germline variants in blood, saliva, and buccal swab samples |
Is the cancer gone or has it returned?
Innovation in development
| WHAT | Exact Sciences is developing the Oncodetect™ test, a tumor-informed molecular residual disease (MRD) test for patients diagnosed with solid tumor cancers |
| WHY | The Oncodetect test is designed to be used in many ways:
|
| HOW | By identifying somatic alterations in DNA extracted from the tumor tissue and detecting a subset of these mutations in circulating tumor DNA (ctDNA) that may be present in an individual’s blood |
Are there personalized options for advanced cancer?
The OncoExTra® test can give you insights
| WHAT | An ultra-comprehensive, ultra-personalized genomic profiling test that looks at DNA+RNA in nearly 20,000 genes8 |
| WHY | To identify the biomarkers associated with targeted therapy, immunotherapy, and clinical trials |
| HOW | Uncovers clinically actionable mutations and fusions through whole-exome, whole-transcriptome, patient-matched tumor-normal sequencing8 |
Learn More About
Innovation in development
| WHAT | Exact Sciences is developing the Oncoliquid™ test, a liquid biopsy test offering a complementary option to tissue-based testing with the OncoExTra test |
| WHY | To identify the most appropriate therapy or clinical trial options for patients with solid tumors, utilizing a simple blood draw |
| HOW | Identifies clinically actionable mutations through detecting and interrogating fragments of circulating tumor DNA (ctDNA) found in the patient’s bloodstream |
-
References